论文部分内容阅读
目的对急性心肌梗死静脉溶栓治疗的临床疗效与安全性进行分析。方法选取本院于2011年5月~2013年9月收治急性心肌梗死患者72例,随机分为对照组与观察组各36例,对照组给予常规治疗,观察组在常规治疗基础上给予链激酶静脉溶栓治疗,对两组患者冠脉临床疗效与并发症发生情况进行观察。结果观察组冠脉再通率显著高于对照组,3 d后胸痛症状发生率显著低于对照组,心律失常、血尿、心源性休克等并发症发生率均显著高于对照组(P<0.05)。结论静脉溶栓方法在急性心肌梗死治疗中具有显著疗效,可有效改善患者临床症状,促进冠脉再通,值得在临床中推广。
Objective To analyze the clinical efficacy and safety of intravenous thrombolysis in patients with acute myocardial infarction. Methods Seventy-two patients with acute myocardial infarction who were admitted to our hospital from May 2011 to September 2013 were randomly divided into control group and observation group with 36 cases each. The control group was given routine treatment. The observation group was given streptokinase Intravenous thrombolysis, the clinical efficacy and complications of two groups of patients with coronary artery disease were observed. Results The rate of coronary recanalization in the observation group was significantly higher than that in the control group. The incidence of chest pain symptom after 3 days was significantly lower than that of the control group. The incidence of complications such as arrhythmia, hematuria and cardiogenic shock were significantly higher than those in the control group (P < 0.05). Conclusion Intravenous thrombolysis has a significant effect in the treatment of acute myocardial infarction, which can effectively improve the clinical symptoms and promote the recanalization of coronary artery. It is worth to be popularized clinically.